Drug Development

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Intraneuronal tau aggregates are key pathological hallmarks of Alzheimer's disease (AD).
• Impaired protein degradation pathways, like the ubiquitin-proteasome system, worsen tau accumulation.
• Proteolysis-Targeting Chimeras (PROTACs) offer a novel strategy to induce targeted protein degradation.

Purpose of the Study:

• To develop novel small-molecule PROTACs for promoting tau degradation.
• To investigate the potential of PROTACs as a therapeutic approach for AD.

Main Methods:

• In silico library generation and ternary complex formation modeling of PROTACs.
• Prediction of pharmacokinetic properties and molecular dynamics simulations for stability and permeability.
• Evaluation of PROTACs in cellular models (SH-SY5Y, primary neurons) using western blot, immunofluorescence, and proteasome/autophagy inhibition.

Main Results:

• Computational modeling identified over 25 PROTACs with enhanced ternary complex formation potential.
• Pharmacokinetic predictions indicate good oral bioavailability, brain permeability, and low toxicity for several PROTAC candidates.
• In vitro studies show PROTACs can reverse Aβ42-induced tau hyperphosphorylation in primary neurons.

Conclusions:

• Novel small-molecule PROTACs demonstrate potential for effectively degrading tau aggregates.
• PROTAC technology holds promise for developing breakthrough treatments for AD and other neurodegenerative diseases.